Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

This cohort study examines neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) after the second and third doses of the BNT162b2 mRNA vaccine among Danish adults.

Detalles Bibliográficos
Autores principales: Lassaunière, Ria, Polacek, Charlotta, Frische, Anders, Boding, Lasse, Sækmose, Susanne Gjørup, Rasmussen, Morten, Fomsgaard, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107029/
https://www.ncbi.nlm.nih.gov/pubmed/35560054
http://dx.doi.org/10.1001/jamanetworkopen.2022.12073
_version_ 1784708401646796800
author Lassaunière, Ria
Polacek, Charlotta
Frische, Anders
Boding, Lasse
Sækmose, Susanne Gjørup
Rasmussen, Morten
Fomsgaard, Anders
author_facet Lassaunière, Ria
Polacek, Charlotta
Frische, Anders
Boding, Lasse
Sækmose, Susanne Gjørup
Rasmussen, Morten
Fomsgaard, Anders
author_sort Lassaunière, Ria
collection PubMed
description This cohort study examines neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) after the second and third doses of the BNT162b2 mRNA vaccine among Danish adults.
format Online
Article
Text
id pubmed-9107029
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-91070292022-05-27 Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine Lassaunière, Ria Polacek, Charlotta Frische, Anders Boding, Lasse Sækmose, Susanne Gjørup Rasmussen, Morten Fomsgaard, Anders JAMA Netw Open Research Letter This cohort study examines neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) after the second and third doses of the BNT162b2 mRNA vaccine among Danish adults. American Medical Association 2022-05-13 /pmc/articles/PMC9107029/ /pubmed/35560054 http://dx.doi.org/10.1001/jamanetworkopen.2022.12073 Text en Copyright 2022 Lassaunière R et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Lassaunière, Ria
Polacek, Charlotta
Frische, Anders
Boding, Lasse
Sækmose, Susanne Gjørup
Rasmussen, Morten
Fomsgaard, Anders
Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
title Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
title_full Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
title_fullStr Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
title_full_unstemmed Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
title_short Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
title_sort neutralizing antibodies against the sars-cov-2 omicron variant (ba.1) 1 to 18 weeks after the second and third doses of the bnt162b2 mrna vaccine
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107029/
https://www.ncbi.nlm.nih.gov/pubmed/35560054
http://dx.doi.org/10.1001/jamanetworkopen.2022.12073
work_keys_str_mv AT lassauniereria neutralizingantibodiesagainstthesarscov2omicronvariantba11to18weeksafterthesecondandthirddosesofthebnt162b2mrnavaccine
AT polacekcharlotta neutralizingantibodiesagainstthesarscov2omicronvariantba11to18weeksafterthesecondandthirddosesofthebnt162b2mrnavaccine
AT frischeanders neutralizingantibodiesagainstthesarscov2omicronvariantba11to18weeksafterthesecondandthirddosesofthebnt162b2mrnavaccine
AT bodinglasse neutralizingantibodiesagainstthesarscov2omicronvariantba11to18weeksafterthesecondandthirddosesofthebnt162b2mrnavaccine
AT sækmosesusannegjørup neutralizingantibodiesagainstthesarscov2omicronvariantba11to18weeksafterthesecondandthirddosesofthebnt162b2mrnavaccine
AT rasmussenmorten neutralizingantibodiesagainstthesarscov2omicronvariantba11to18weeksafterthesecondandthirddosesofthebnt162b2mrnavaccine
AT fomsgaardanders neutralizingantibodiesagainstthesarscov2omicronvariantba11to18weeksafterthesecondandthirddosesofthebnt162b2mrnavaccine

Ejemplares similares